RecruitingNCT06564571
Artificial Intelligence in Endoscopic Ultrasound
Sponsor
Orlando Health, Inc.
Enrollment
310 participants
Start Date
Jan 19, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Age ≥ 18 years
- Any patient undergoing endoscopic ultrasound examination
Exclusion Criteria1
- Age \< 18 years
Interventions
DEVICEPatients undergoing endoscopic ultrasound procedures
Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06564571
Related Trials
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT056635158 locations
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location